Page last updated: 2024-11-03

pyridinolcarbamate and Carcinogenesis

pyridinolcarbamate has been researched along with Carcinogenesis in 1 studies

Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)

Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yu, Z1
Peng, Y1
Gao, J1
Zhou, M1
Shi, L1
Zhao, F1
Wang, C1
Tian, X1
Feng, L1
Huo, X1
Zhang, B1
Liu, M1
Fang, D1
Ma, X1

Other Studies

1 other study available for pyridinolcarbamate and Carcinogenesis

ArticleYear
The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
    Science advances, 2023, 06-30, Volume: 9, Issue:26

    Topics: Adenocarcinoma of Lung; Carcinogenesis; Cell Transformation, Neoplastic; Cyclooxygenase 2; HSP90 Hea

2023